CDKN2A and carcinoma: Furthermore, Nauta et al. reported that patients with p16-positive/HPV-positive disease showed a significant superior survival compared to the group with p16-positive/HPV-negative tumors, whose survival differences did not significantly differ from patients with p16-negative carcinomas [23], even though this study did not further examine p16-negative tumors with regard to the HPV-status.